Navigation Links
Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
Date:5/18/2011

SUNNYVALE, Calif., May 18, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that a clinical abstract on our Btk inhibitor, PCI-32765, has been selected for an oral presentation at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011 in Chicago, IL. Additionally, two clinical abstracts on PCI-32765 have been selected for oral presentations at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 15-18, 2011.

Pharmacyclics plans to present a material update on the PCI-32765 clinical development program in a press release after the ASCO oral presentation on Monday, June 6, 2011 and expects to hold a conference call as well. The update will encompass the entire PCI-32765 clinical development program and will specifically include: 1) safety and efficacy data with the use of single-agent PCI-32765 in relapsed/ refractory or treatment-naive chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL) in patients with adequate follow-up from our ongoing Phase IB/II trial, including patients with poor-risk disease; 2) an update of efficacy from the Phase 1A trial of PCI-32765 in B-cell malignancies, including mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma and 3) a status update for ongoing PCI-32765 clinical studies, including  a pilot trial of PCI-32765 in the ABC subtype of diffuse large B-cell lymphoma, a phase II trial of single agent PCI-32765 in mantle cell lymphoma, and studies with PCI-32765 in combination with either bendamustine/rituximab (BR), fludarabine/cyclophosphamide/rituximab (FCR), or ofatumumab in CLL. Oral Abstract Data Presentation at ASCO, Chicago (June 3 – 7, 2011)Abstract #6508Title: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study. J.C. Byrd et al.Date/Time: Monday, June 6, 2011; Oral Abstract Session: 9:30 AM – 12:30 PMSession Title: Leukemia, Myelodysplasia and TransplantationLocation: Arie Crown TheaterOral Abstract Data Presentations at ICML, Lugano, Switzerland (June 15-18, 2011)Abstract # 122Title: The Btk Inhibitor PCI-32765 is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study.  S. O'Brien et al. Date/Time: Friday, June 17, 2011; 9:45 AMSession 10: Chronic Lymphocytic Leukemia (CLL)Location: Room A, B, C and Marquee Parco Ciani)Abstract # 153Title: The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B-cell malignancies: Final results from a Phase Ia study.  R.H. Advani et al.Date/Time: Saturday, June 18, 2011; 9:30 AMSession 14:  Signaling Pathways in LymphomaLocation: Room AAbout PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
2. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
3. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
4. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
5. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
6. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
7. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
8. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
9. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
10. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016 The new report "Global Blood Monitoring ... Acuity Business Research & Consulting group reveals that global market for ... million in 2014 and expected to grow to US$ 24,830.1 million ... North America , Europe ... , Middle-East and Africa ...
(Date:2/9/2016)... BRUNSWICK, N.J. , Feb. 9, 2016  Johnson ... the RBC Capital Markets Global Healthcare Conference on Tuesday, ... York City.  Dominic Caruso , Vice President, Finance ... Worldwide Chairman, Consumer will represent the Company in a ... www.investor.jnj.com . --> www.investor.jnj.com . ...
(Date:2/9/2016)... , Feb. 9, 2016  Bluestar Silicones will promote ... line for long-term implant applications and announce certification ... & Manufacturing (MD&M) West Conference (Booth #1759), February ... --> --> Available in ... LSRs offer outstanding physical properties enabling our customers ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... February is Heart Awareness ... Rate Variability scans throughout the month to the American Heart Association, New Mexico chapter. ... signs of heart disease and Health Quest’s INSiGHT Pulse Wave Profiler utilizes a non-invasive ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study ... rates and Medicare rates for a variety of medical services in Illinois as ... of the 2015 Fee Schedule Rates in Illinois, are professional medical services, ...
(Date:2/9/2016)... California (PRWEB) , ... February ... ... automated print and e-book publishing software, in partnership with Snowfall4pod Digital, creators ... – a comprehensive book publishing, content management, global distribution and print-on-demand network. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Establishment Labs, a global breast implant ... to the company´s Board of Directors. , “We are honored to welcome ... exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge and ...
(Date:2/9/2016)... ... ... Journal of Pain Research has published the commentary “ Terminology of chronic ... John F. Peppin says “Terminology matters, yet little attention has been paid to the ... pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the distinction here ...
Breaking Medicine News(10 mins):